Blackrock’s Sending THIS Crypto Higher on Purpose

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

Anthony Scott Praill net worth and biography

Anthony Praill Biography and Net Worth

CFO of Kura Oncology

Scott Praill, CPA, BSc. has been our Chief Financial Officer since January 29, 2013 and previously served as a consultant to Del Mar Pharmaceuticals (BC) Ltd. From 2004 to January 2013, Mr. Praill was an independent consultant providing accounting and administrative services to companies in the resource industry. Mr. Praill served as CFO of Strata Oil & Gas, Inc. from June 2007 to September 2008. From November 1999 to October 2003, Mr. Praill was Director of Finance at Inflazyme Pharmaceuticals Ltd. Mr. Praill completed his articling at Price Waterhouse (now PricewaterhouseCoopers LLP) and obtained his Chartered Professional Accountant designation in 1996. Mr. Praill obtained his Certified Public Accountant (Illinois) designation in 2001. Mr. Praill received a Financial Management Diploma (Honors), from the British Columbia Institute of Technology in 1993, and a Bachelor of Science from Simon Fraser University in 1989.

How do I contact Anthony Scott Praill?: The corporate mailing address for Mr. Praill and other Kura Oncology executives is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. Kura Oncology can also be reached via phone at (858) 500-8800 and via email at [email protected]. Learn More on Anthony Scott Praill's contact information.
Has Anthony Scott Praill been buying or selling shares of Kura Oncology?: Anthony Scott Praill has not been actively trading shares of Kura Oncology over the course of the past ninety days. Most recently, on Wednesday, December 8th, Anthony Scott Praill bought 820 shares of Kura Oncology stock. The stock was acquired at an average cost of $23.80 per share, with a total value of $19,516.00. Learn More on Anthony Scott Praill's trading history.
Who are Kura Oncology's active insiders?: Kura Oncology's insider roster includes Laura Johnson (Director), Anthony Praill (CFO), and Saiid Zarrabian (Insider). Learn More on Kura Oncology's active insiders.
Are insiders buying or selling shares of Kura Oncology?: In the last twelve months, insiders at the sold shares 5 times. They sold a total of 99,534 shares worth more than $2,004,336.81. The most recent insider tranaction occured on May, 20th when insider Teresa Brophy Bair sold 2,615 shares worth more than $57,922.25. Insiders at Kura Oncology own 5.5% of the company. Learn More about insider trades at Kura Oncology.
Information on this page was last updated on 5/20/2024.

Anthony Scott Praill Insider Trading History at Kura Oncology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/8/2021	Buy	820	$23.80	$19,516.00

Anthony Scott Praill Buying and Selling Activity at Kura Oncology

Kura Oncology Company Overview

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Today's Range

Now: $16.49

$16.41

$17.93

50 Day Range

MA: $18.63

$16.72

$21.08

2 Week Range

Now: $16.49

$8.80

$24.17

Volume

734,891 shs

Average Volume

895,012 shs

Market Capitalization

$1.28 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86